The Hepatitis B Diagnostic Tests Market was projected to reach US$ 872.5 million in 2022. Due to the increasing prevalence of hepatitis B worldwide, it is predicted that the market as a whole will grow at a CAGR of 6.4% between 2022 and 2028, reaching a valuation of US$ 1.26 Million by the end of that year.
A significant sector of the global healthcare market, the Hepatitis B Diagnostic Tests Market, is focused on the identification and surveillance of Hepatitis B virus infections. A viral infection known as hepatitis B that affects the liver can result in major health issues like liver cancer and cirrhosis. The market for diagnostic tests is crucial to the early detection of Hepatitis B, enabling prompt medical attention and better outcomes.
Over the years, the Hepatitis B Diagnostic Tests Market has witnessed significant advancements in technology, resulting in more accurate and efficient testing methods. Traditional tests like serological assays and enzyme immunoassays have been complemented by molecular diagnostic techniques such as PCR (Polymerase Chain Reaction) and nucleic acid testing, allowing for quicker and more precise identification of the virus.
Empower your decisions with data-driven insights from our Sample Report – Get It Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-1332
This market’s growth is driven by the increasing prevalence of Hepatitis B infections worldwide and the rising awareness of the importance of early detection and treatment. Additionally, government initiatives and healthcare organizations’ efforts to curb the spread of Hepatitis B have further boosted the demand for diagnostic tests.
The Hepatitis B Diagnostic Tests Market is highly competitive, with key players continuously innovating to develop cutting-edge diagnostic solutions. These innovations aim to provide not only accurate results but also cost-effective and accessible testing options for a broader population. As the healthcare sector continues to evolve, the Hepatitis B Diagnostic Tests Market will remain a vital component in the global fight against this viral infection, contributing to better patient care and overall public health.
High Prevalence of Hepatitis B in the APEJ Region Boosting Global Market Revenue Growth
The prevalence of hepatitis B is highest in the APEJ region and the disease burden caused by chronic cases of hepatitis B is enormous. APEJ region has more number of chronic hepatitis B patients than any other region in the world and is thus a potential market for hepatitis B test kit manufacturers. As per the data provided by WHO, China accounts for one-third of all chronic hepatitis B infections. In addition, 6.2% of the adult population in the Western Pacific region is infected with hepatitis B.
In the South-East Asia region, an estimated 2% of the general population is infected with hepatitis B. According to Hepatitis Australia, approximately 225,000 people are living with chronic hepatitis B in the country. As per the data provided by WHO, in India, the prevalence of hepatitis B surface antigen is 3%-4.2% with over 40 million hepatitis B carriers. Due to such high prevalence of hepatitis B in the APEJ region, the market for hepatitis B diagnostic tests has a huge potential in the region.
Global Hepatitis B Diagnostic Tests Market: Segmentation and Forecast:
The global hepatitis B diagnostic tests market is segmented on the basis of product type, end user and region.
- On the basis of product type, the enzyme immunoassay kits segment was estimated to be valued at nearly US$ 590 Million in the year 2022 and is likely to reach a valuation of nearly US$ 1,100 Million in 2028, accounting for a CAGR of 6.2% during the assessment period 2022-2028.
- On the basis of end user, the hospitals segment was estimated to be valued at nearly US$ 250 Million in 2022 and is estimated to reach a valuation of nearly US$ 460 Million in 2028, registering a CAGR of 6.1% during the period of assessment.
- On the basis of region, the APEJ hepatitis B diagnostic tests market was estimated to be valued at nearly US$ 200 Million in 2022 and is likely to reach a valuation of nearly US$ 380 Million in 2028, accounting for a CAGR of 7.2% during the period of forecast.
The HBV diagnostic assays typically involves several steps, including medical history, physical examination, blood tests, and imaging studies
Global Hepatitis B Diagnostic Tests Market: Competitive Landscape
- Bio-Rad Laboratories, Inc.
- DiaSorin S.p.A.
- Abbott Laboratories
- Meridian Bioscience
- bioMérieux SA Inc.
- Vista Diagnostics International
- Biogate Laboratories Ltd.
- J.Mitra & Co. Ltd.
- Siemens Medical Solutions USA, Inc.
- General Biologicals Corporation
See Beyond The Ordinary With Our Extraordinary Methodology Insights Today! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1332
Hepatitis B Diagnostic Tests Market By Category
Product Type:
- Enzyme Immunoassay Kits
- Hepatitis B Surface Antigen Test
- Anti-Hepatitis B Surface Antibody Test
- Anti-Hepatitis B Core Antibody Test
- Point-of-Care Testing Kits
- Strips
- Cassettes/Cards
End User:
- Hospitals
- Clinics
- Diagnostic Centres
- Home Care
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
